このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

重症好酸球性喘息の小児患者におけるベンラリズマブの多施設、無作為化、二重盲検、並行群間、プラセボ対照、初回喘息増悪までの時間の第 III 相有効性および安全性試験(DOMINICA) (DOMINICA)

2026年10月27日 更新者:AstraZeneca

重度好酸球性喘息の小児患者におけるベンラリズマブの有効性と安全性(ドミニカ)

A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.

調査の概要

状態

積極的、募集していない

条件

詳細な説明

A randomised, double-blind, parallel-group, placebo-controlled, time-to-first-asthma-exacerbation event study designed.

There will be a screening period of 2 months to allow adequate time for the eligibility criteria to be evaluated. The screening period may be reduced to not lesser than 4 weeks from Visit 2a. Furthermore, the Screening Period may be extended up to 12 weeks (or longer, if deemed necessary by the investigator), to accommodate treatment.

Visit 2 will be split into Part A (Visit 2a) and Part B (Visit 2b) to reassess eligibility prior to randomisation and first dose of study treatment administration.

Patients will be randomised 1:1 to receive benralizumab or placebo.

The treatment period will consist of 2 parts: double-blind (DB) treatment period and open-label extension (OLE) period.

The initial placebo-controlled, DB treatment period will be of variable duration. The minimum duration of treatment in the DB treatment period for each patient will be 16 weeks. Patient will continue in the DB treatment period until the patient experiences an exacerbation or the required number of events have been observed in the study, whichever occurs sooner.

All patients who experience an asthma exacerbation in the DB treatment period will be offered the opportunity to continue into the OLE period. The OLE period is intended to allow each patient at least 48 weeks in the ≥ 12 to < 18-year-old age group and at least 2 years (104 weeks) in the ≥ 6 to < 12-year-old age group, of treatment with benralizumab.

An end-of-the-treatment visit will occur 8 weeks after the last dose in the OLE.

研究の種類

介入

入学 (実際)

94

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Torrance、California、アメリカ、90505
        • Research Site
    • Florida
      • Ocala、Florida、アメリカ、34471
        • Research Site
    • Kentucky
      • Owensboro、Kentucky、アメリカ、42301
        • Research Site
    • Louisiana
      • Lafayette、Louisiana、アメリカ、70508
        • Research Site
    • Missouri
      • Kansas City、Missouri、アメリカ、64108
        • Research Site
    • New Jersey
      • Northfield、New Jersey、アメリカ、08225
        • Research Site
    • New York
      • The Bronx、New York、アメリカ、10459
        • Research Site
    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • Research Site
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • Research Site
    • Texas
      • San Antonio、Texas、アメリカ、78229
        • Research Site
      • Tyler、Texas、アメリカ、75708
        • Research Site
      • Ciudad de Buenos Aire、アルゼンチン、C1425DTG
        • Research Site
      • Ciudad de Buenos Aires、アルゼンチン、C1414AIF
        • Research Site
      • Florida、アルゼンチン、B1602DQD
        • Research Site
      • Lobos、アルゼンチン、7240
        • Research Site
      • Mar del Plata、アルゼンチン、B7600
        • Research Site
      • Mendoza、アルゼンチン、5500
        • Research Site
      • Mendoza、アルゼンチン、M5500CCG
        • Research Site
      • Rosario、アルゼンチン、2000
        • Research Site
      • San Juan Bautista、アルゼンチン、1888
        • Research Site
      • Santa Fe、アルゼンチン、S3000ASF
        • Research Site
      • London、イギリス、SE5 9RS
        • Research Site
      • Manchester、イギリス、M13 9PL
        • Research Site
      • Milan、イタリア、20142
        • Research Site
      • Roma、イタリア、00165
        • Research Site
      • Badalona、スペイン、08916
        • Research Site
      • Barcelona、スペイン、8035
        • Research Site
      • Benalmádena、スペイン、29631
        • Research Site
      • Esplugues de Llobregat、スペイン、8950
        • Research Site
      • Créteil、フランス、94010
        • Research Site
      • Lyon、フランス、69394
        • Research Site
      • Rouen、フランス、76031
        • Research Site
      • Bialystok、ポーランド、15-879
        • Research Site
      • Krakow、ポーランド、31-624
        • Research Site
      • Lodz、ポーランド、90-302
        • Research Site
      • Skarżysko-Kamienna、ポーランド、26-110
        • Research Site
      • Tarnów、ポーランド、33-100
        • Research Site
      • Kaohsiung City、台湾、833
        • Research Site
      • Taoyuan、台湾、333
        • Research Site
      • Cheongju-si、韓国、28644
        • Research Site
      • Junggu、韓国、22332
        • Research Site
      • Seoul、韓国、03080
        • Research Site
      • Seoul、韓国、05505
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6年~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Capable of giving assent (signing the assent form) to participate in the study. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.

  • Patient and the caregiver (where applicable) must be willing to and be able to answer questionnaires that are part of the study procedures.

  • Male or female patients aged ≥ 6 to < 18 years old.

  • Patients with physician-diagnosed severe eosinophilic asthma for at least 12 months prior to Visit 1.

  • Patients with a diagnosis of severe asthma confirmed, evaluated, and managed by the clinical site/site network for ≥ 6 months prior to Visit 1.

  • Patients with an exacerbation history of asthma exacerbations (defined as a requirement for systemic corticosteroids and/or hospitalisation) within 12 months prior to Visit 1, OR,

    1. 2 asthma exacerbations (defined as a requirement for systemic corticosteroids and/or hospitalisation) per year within the 2 years prior to Visit 1 AND, one or more of the following:
    2. Currently on stable maintenance oral corticosteroids (OCS) used for at least 3 months prior to Visit 1, OR,
    3. At least one of the 2 exacerbations that occurred in the year prior to Visit 1 resulted in hospitalisation.
  • Patients on well-documented, stable treatment for asthma with high dose ICS and at least one additional controller medication, such as long-acting β2 agonists (LABA), leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or theophylline, since at least 6 months prior to Visit 1.

  • Eosinophilic airway inflammation that is related to asthma characterised as eosinophilic in nature as indicated by peripheral blood eosinophil count of ≥ 300 cells/μL during screening OR a blood eosinophil count of 150 to 299 cells/μL and documentation of elevated eosinophils in bronchoalveolar lavage (BAL), sputum or bronchial biopsy within the 2 years prior to Visit 1.

  • ≥ 70% compliance with maintenance asthma medication during the screening period based on the Paediatric Asthma Symptom - Observer reported (PASO) or Asthma Daily Diary.

  • At least 70% daily PASO or Asthma Daily Diary completion during the entire screening period, with at least 50% PASO or Asthma Daily Diary completion in the 14-day period prior to randomisation.

  • Pre-BD FEV1 ≤ 95% of the predicted normal value or pre-BD FEV1/forced vital capacity (FVC) ratio < 0.85 required at Visit 1. Patients with ≥ 25 % increase in pre-BD FEV1 value during the screening period will be screen failed.

  • ACQ-IA ≥ 1.5 with no meaningful improvement (ACQ-IA change ≤ -0.5) between screening and Visit 2a.

  • Body weight ≥ 15 kg.

  • Females of childbearing potential (FOCBP) who are sexually active, as judged by the investigator, must commit to consistent and correct use of a highly effective method of contraception.

Exclusion Criteria:

  • Clinically important pulmonary disease other than asthma or patients who have ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts.
  • Life-threatening asthma.
  • Asthma exacerbation requiring use of systemic corticosteroids or increase in maintenance dose of OCS within 2 weeks prior to Visit 2a or acute upper/lower respiratory infection that requires antibiotics or antiviral medication within 2 weeks prior to the first dose of the IP (Visit 2b).
  • Any disorder that is not stable in the opinion of the investigator and could affect the safety of the patient during the study, influence the findings of the studies or their interpretations or impede the patient's ability to complete the entire duration of the study.
  • History of anaphylaxis to any biologic therapy.
  • Current malignancy, or history of malignancy.
  • A helminth parasitic infection.
  • Use of immunosuppressive medication.
  • Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
  • Receipt of any marketed or investigational biologic within 5 half-lives prior to Visit 1.
  • Previously received benralizumab (MEDI-563).
  • Participation in another interventional clinical study.
  • Patients with known hypersensitivity to benralizumab or any of the excipients of the product.
  • Currently pregnant, breastfeeding, or lactating females.
  • Previous randomisation in the present study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Benralizumab

Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.

Benralizumab active solution will be administered SC to the patients.

プラセボコンパレーター:Placebo

Patients will receive a matching solution of the placebo via SC injection.

Placebo solution will be administered SC to the patients.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time to first asthma exacerbation
時間枠:From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period

The effect of benralizumab on asthma exacerbations in paediatric and adolescent patients with uncontrolled asthma will be evaluated.

From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA)
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on asthma control and symptoms will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Change from baseline, during the DB treatment period in Asthma symptom score
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on asthma control and symptoms will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Change from baseline, during the DB treatment period in rescue medication use
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on asthma control and symptoms will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Change from baseline, during the DB treatment period in night-time awakenings due to asthma
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on asthma control and symptoms will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Change from baseline, during the DB treatment period in peak expiratory flow (PEF)
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on asthma control and symptoms will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Serum benralizumab trough concentration
時間枠:During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period

The pharmacokinetics of benralizumab will be characterised.

During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period
Anti-benralizumab antibodies
時間枠:During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period

The immunogenicity of benralizumab will be characterised.

During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period
Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on asthma health-related quality of life will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on pulmonary function (FEV1) will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1
時間枠:From Baseline (Week 0) to EOT in DB treatment period

The effect of benralizumab on pulmonary function (FEV1) will be assessed.

From Baseline (Week 0) to EOT in DB treatment period
The Annualised asthma exacerbation rate (AAER) in the DB treatment period
時間枠:From Screening until the EOT double blind treatment period

The asthma exacerbations reported during the DB treatment period of the study will be described.

From Screening until the EOT double blind treatment period

その他の成果指標

結果測定
メジャーの説明
時間枠
Number of patients with Adverse events (AEs) and Serious adverse events (SAEs)
時間枠:From Screening period until EOT DB treatment period

The safety and tolerability of benralizumab will be evaluated.

From Screening period until EOT DB treatment period
The AAER in the OLE period
時間枠:From Week 0 until the EOT OLE period

The annualised rate of severe exacerbations in the OLE period will be assessed.

From Week 0 until the EOT OLE period

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年4月5日

一次修了 (推定)

2026年12月23日

研究の完了 (推定)

2026年12月23日

試験登録日

最初に提出

2023年1月11日

QC基準を満たした最初の提出物

2023年1月11日

最初の投稿 (実際)

2023年1月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月28日

QC基準を満たした最後の更新が送信されました

2026年10月27日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

IPD 共有時間枠

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有アクセス基準

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する